Eleven Biotherapeutics Reports Third Quarter 2015 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/19/2026
- Wall St up after tech selloff as yields retreat; Moderna surges
- U.S. Treasury doubles buyback operation size for long-dated bonds
- Marvell shares jump after giving Google warrants amid custom chip deal
- Nvidia credit risk gauge hits new peak as SoftBank readies record bond issue
- Deutsche Bank calls Treasury buyback doubling similar to ’operation twist’
- Marvell issues Google warrant tied to custom chip deal
- Tech selloff weighs down Wall Street as bond yields climb
- Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
- Francisco Partners to acquire Weave Communications for $650M
Eleven Biotherapeutics (EBIO) Misses Q3 EPS by 17c
November 4, 2015 7:48 AM ESTEleven Biotherapeutics (NASDAQ: EBIO) reported Q3 EPS of ($0.50), $0.17 worse than the analyst estimate of ($0.33). Revenue for the quarter came in at $68 thousand versus the consensus estimate of $100 thousand.
For earnings history and earnings-related data on Eleven Biotherapeutics (EBIO) click here.
... More